Personalized medicine policy challenges: Measuring clinical utility at point of care

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 3, 2012, Pages 289-295

  Van Rooij, Tibor ^a   Wilson, Donna M ^a   Marsh, Sharon ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

case studies; clinical uptake; economic evaluation; genomics; information technology; patient outcomes; personalized medicine; pharmacogenomics; point of care; policy change

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMATINIB; IRINOTECAN; TRASTUZUMAB; WARFARIN;

BIOINFORMATICS; BLEEDING; BREAST CANCER; BREAST METASTASIS; CLINICAL DECISION MAKING; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DNA DETERMINATION; DRUG MEGADOSE; DRUG SURVEILLANCE PROGRAM; ECONOMIC EVALUATION; GENE OVEREXPRESSION; GENOTYPE; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; INFORMATION TECHNOLOGY; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; PERSONALIZED MEDICINE; PHARMACOGENOMICS; POINT OF CARE TESTING; REVIEW;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HEALTH POLICY; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL INFORMATICS; PHARMACOGENETICS; POINT-OF-CARE SYSTEMS; POLICY MAKING; TREATMENT OUTCOME;

EID: 84864200150     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.12.15     Document Type: Review

References (57)

1. EVans WE, McLeod HL Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003
2. Marsh S, Van Rooij T. Challenges of incorporating pharmacogenomics into clinical practice. Gastrointest. Cancer Res. 3(5), 206-207 (2009
3. Van Rooij T, Marsh S. Improving oncology outcomes through targeted therapeutics will require electronic delivery systems. Future Oncol. 7(5), 649-656 (2011
4. De La Calle G, Van Mulligen EM, Molero E et al. Education and research in INFOBIOMED, the European Network of Excellence in Biomedical Informatics. AMIA Annu. Symp. Proc. 11, 927 (2007
5. Maojo V, Crespo J, De La Calle G, Barreiro J, Garcia-Remesal M. Using web services for linking genomic data to medical information systems. Methods Inf. Med 46(4), 484-492 (2007
6. Epstein RS, Teagarden JR. Comparative effectiveness research and personalized medicine: Catalyzing or colliding? Pharmacoeconomics 28(10), 905-913 (2010
7. Issa AM. Personalized medicine and the practice of medicine in the 21st century. Mcgill J. Med. 10(1), 53-57 (2007
8. Frueh FW. Back to the future: Why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine. Pharmacogenomics 10(7), 1077-1081 (2009
9. Titler MG. Translation science and context. Res. Theory Nurs. Pract. 24(1), 35-55 (2010
10. Al Mallah A, Guelpa P, Marsh S, Van Rooij T. Integrating genomic-based clinical decision support into electronic health records. Pers. Med. 7, 163-170 (2010
11. Gurwitz D, Zika E, Hopkins MM, Gaisser S, Ibarreta D. Pharmacogenetics in Europe: Barriers and opportunities. Public Health Genomics 12(3), 134-141 (2009
12. Yin RK. Enhancing the quality of case studies in health services research. Health Serv. Res. 34(5 Pt 2), 1209-1224 (1999
13. Ullman-Cullere MH, Mathew JP. Emerging landscape of genomics in the Electronic Health Record for personalized medicine Hum. Mutat. 32(5), 512-516 (2011
14. Bouffard M, Phillips MS, Brown AM, Marsh S, Tardif JC, Van Rooij T. Damming the genomic data flood using a comprehensive analysis and storage data structure. Database (Oxford)2010, article ID: Baq029 (2010
15. Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE. Genetic warfarin dosing: Tables versus algorithms. J. Am. Coll. Cardiol. 57(5), 612-618 (2011)
16. Kawamoto K, Lobach DF, Willard HF, Ginsburg GS. A national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicine. BMC Med. Inform. Decis. Mak. 9, 17 (2009
17. Van Rooij T. Behind the PGx challenge: Biofx. Genome Technol. July/August, 19-20 (2007
18. Saito Y, Oshitanai R, Terao M et al. Post-marketing safety evaluation of S-1 in patients with inoperable or recurrent breast cancer: Especially in patients treated with S-1 + trastuzumab. Jpn. J. Clin. Oncol 41(9), 1051-1058 (2011
19. Obradovic M, Mrhar A, Kos M. Market uptake of biologic and small-molecule-targeted oncology drugs in Europe. Clin. Ther. 31(12), 2940-2952 (2009
20. Becla L, Lunshof JE, Gurwitz D et al. Health technology assessment in the era of personalized health care. Int. J. Technol. Assess. Health Care 27(2), 118-126 (2011
21. Marsh S. Impact of pharmacogenomics on clinical practice in oncology. Mol. Diagn. Ther. 11(2), 79-82 (2007
22. Chiang A, Million RP. Personalized medicine in oncology: next generation. Nat. Rev. Drug Discov. 10(12), 895-896 (2011
23. Kung S, Allen JD. Patients and clinicians report higher-than-average satisfaction with psychiatric genotyping for depressed inpatients. J. Clin. Psychiatr. 71, 745-753 (2011
24. Newman WG, Payne K, Tricker K et al.; TARGET study recruitment team. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to zathioprine treatment: The ARGET study. Pharmacogenomics 12(6), 815-826 (2011
25. Payne K, Fargher EA, Roberts SA et al. Valuing pharmacogenetic testing services: A comparison of patients' and health care professionals' preferences. Value Health 14(1), 121-134 (2011
26. Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008)
27. Phillips MS, Hihi AK, Van Rooij T et al. Génome Québec & Montreal Heart Institute Pharmacogenomics Centre: A translational pharmacogenomics platform - from R&D to the clinic. Pharmacogenomics 9(10), 1391-1396 (2008
28. American Pharmacists Association. Integrating pharmacogenomics into pharmacy practice via medication therapy management. J. Am. Pharm. Assoc. 51, e64-e74 (2011
29. Epstein RS, Moyer TP, Aubert RE et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study)J. Am. Coll. Cardiol 55(25), 2804-2812 (2010
30. Khoury MJ, Rich EC, Randhawa G, Teutsch SM, Niederhuber J. Comparative effectiveness research and genomic medicine: An evolving partnership for 21st century medicine. Genet. Med. 11(10), 707-711 (2009
31. Dodson C. Knowledge and attitudes concerning pharmacogenomics among healthcare professionals. Pers. Med. 8, 421-428 (2011
32. Bonter K, Desjardins C, Currier N, Pun J, Ashbury FD. Personalised medicine in Canada: A survey of adoption and practice in oncology, cardiology and family medicine. BMJ Open 1(1), e000110 (2011
33. Roederer MW, McLeod H, Juliano JJ. Can pharmacogenomics improve malaria drug policy? Bull. World Health Organ. 89(11), 838-845 (2011
34. Johnson JA, Gong L, Whirl-Carrillo M et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90(4), 625-629 (2011
35. Ferrusi IL, Marshall DA, Kulin NA, Leighl NB, Phillips KA. Looking back at 10 years of trastuzumab therapy: What is the role of HER2 testing? A systematic review of health economic analyses. Pers. Med. 6(2), 193-215 (2009
36. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: Regulatory, scientific, and clinical issues. J. Thromb. Thrombolysis 25(1), 45-51 (2008
37. Rieder MJ, Reiner AP, Gage BF et al Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005
38. Plosker GL, Keam SJ. Trastuzumab: A review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs 66(4), 449-475 (2006)
39. Dent S, Verma Sh, Latreille J et al. The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer. Curr. Oncol. 16(4), 25-35 (2009
40. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat. Med. 7(5), 548-552 (2001
41. Engel RH, Kaklamani VG. HER2-positive breast cancer: Current and future treatment strategies. Drugs 67(9), 1329-1341 (2007
42. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuVant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005
43. Nahta R, Esteva FJ. Trastuzumab: Triumphs and tribulations. Oncogene 26(25), 3637-3643 (2007
44. Ameyaw MM, Tayeb M, Thornton N et al. Ethnic variation in the HER-2 codon 655genetic polymorphism previously associated with breast cancer. J. Hum. Genet. 47(4), 172-175 (2002
45. Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling. Mol. Cancer Ther. 6(2), 667-674 (2007
46. Marsh S, Hoskins JM. Irinotecan pharmacogenomics. Pharmacogenomics 11(7), 1003-1010 (2010
47. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1.*28 genotype and irinotecan-induced neutropenia: Dose matters. J. Natl Cancer Inst. 99(17), 1290-1295 (2007
48. Cecchin E, Innocenti F, D'Andrea M et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J. Clin. Oncol. 27(15), 2457-2465 (2009
49. Hoskins JM, Marcuello E, Altes A et al Irinotecan pharmacogenetics: Influence of pharmacodynamic genes. Clin. Cancer Res. 14(6), 1788-1796 (2008
50. de Jong FA, Scott-Horton TJ, Kroetz DL et al. Irinotecan-induced diarrhea: Functional significance of the polymorphic ABCC2 transporter protein. Clin. Pharmacol. Ther. 81(1), 42-49 (2007
51. Millar JA, Millward MJ. Cost effectiveness of trastuzumab in the adjuVant treatment of early breast cancer: A lifetime model. Pharmacoeconomics 25(5), 429-442 (2007)
52. Matter-Walstra KW, Dedes KJ, Schwenkglenks M, Brauchli P, Szucs TD, Pestalozzi BC. Trastuzumab beyond progression: A cost-utility analysis. Ann. Oncol. 21(11), 2161-2168 (2010
53. Neyt M, Huybrechts M, Hulstaert F, Vrijens F, Ramaekers D. Trastuzumab in early stage breast cancer: A cost-effectiveness analysis for Belgium. Health Policy 87(2), 146-159 (2008
54. Lee JY, Garnett CE, Gobburu JV et al. Impact of pharmacometric analyses on new drug approval and labelling decisions: A review of 198 submissions between 2000 and 2008. Clin. Pharmacokinet. 50(10), 627-635 (2011
55. Haas JS, Phillips KA, Liang SY et al. Genomic testing and therapies for breast cancer in clinical practice. J. Oncol. Pract 7(Suppl. 3), e1s-e7s (2011
56. Ferrusi IL, Leighl NB, Kulin NA, Marshall DA. Do economic evaluations of targeted therapy provide support for decision makers? J. Oncol. Pract. 7(Suppl. 3), S36-S45 (2011
57. Grutters JP, Seferina SC, Tjan-Heijnen VC, Van Kampen RJ, Goettsch WG, Joore MA. Bridging trial and decision: A checklist to frame health technology assessments for resource allocation decisions. Value Health 14(5), 777-784 (2011)